首页> 外文期刊>Frontiers in Microbiology >In Vitro Activities of Nisin and Nisin Derivatives Alone and In Combination with Antibiotics against Staphylococcus Biofilms
【24h】

In Vitro Activities of Nisin and Nisin Derivatives Alone and In Combination with Antibiotics against Staphylococcus Biofilms

机译:乳链菌肽和乳链菌肽衍生物的单独的体外活性,以及​​与抗生素结合的抗葡萄球菌生物膜的活性。

获取原文
           

摘要

The development and spread of pathogenic bacteria that are resistant to the existing catalog of antibiotics is a major public health threat. Biofilms are complex, sessile communities of bacteria embedded in an organic polymer matrix which serve to further enhance antimicrobial resistance. Consequently, novel compounds and innovative methods are urgently required to arrest the proliferation of drug-resistant infections in both nosocomial and community environments. Accordingly, it has been suggested that antimicrobial peptides could be used as novel natural inhibitors that can be used in formulations with synergistically acting antibiotics. Nisin is a member of the lantibiotic family of antimicrobial peptides that exhibit potent antibacterial activity against many Gram-positive bacteria. Recently we have used bioengineering strategies to enhance the activity of nisin against several high profile targets, including multi-drug resistant clinical pathogens such as methicillin-resistant Staphylococcus aureus , vancomycin-resistant enterococci, staphylococci, and streptococci associated with bovine mastitis. We have also identified nisin derivatives with an enhanced ability to impair biofilm formation and to reduce the density of established biofilms of methicillin resistant S. pseudintermedius . The present study was aimed at evaluating the potential of nisin and nisin derivatives to increase the efficacy of conventional antibiotics and to assess the possibility of killing and/or eradicating biofilm-associated cells of a variety of staphylococcal targets. Growth curve-based comparisons established that combinations of derivatives nisin V + penicillin or nisin I4V + chloramphenicol had an enhanced inhibitory effect against S. aureus SA113 and S. pseudintermedius DSM21284, respectively, compared to the equivalent nisin A + antibiotic combinations or when each antimicrobial was administered alone. Furthermore, the metabolic activity of established biofilms treated with nisin V + chloramphenicol and nisin I4V + chloramphenicol combinations revealed a significant decrease in S. aureus SA113 and S. pseudintermedius DSM21284 biofilm viability, respectively, compared to the nisin A + antibiotic combinations as determined by the rapid colorimetric XTT assay. The results indicate that the activities of the nisin derivative and antibiotic combinations represent a significant improvement over that of the wild-type nisin and antibiotic combination and merit further investigation with a view to their use as anti-biofilm agents.
机译:对现有抗生素目录具有抗性的病原细菌的发展和传播是主要的公共卫生威胁。生物膜是嵌入有机聚合物基质中的复杂,无柄的细菌群落,可进一步增强抗微生物性。因此,迫切需要新颖的化合物和创新的方法来阻止在医院和社区环境中耐药菌感染的扩散。因此,已经建议将抗菌肽用作新的天然抑制剂,其可用于具有协同作用的抗生素的制剂中。乳链菌肽是抗微生物肽的羊毛硫抗生素家族的成员,其对许多革兰氏阳性细菌表现出有效的抗菌活性。最近,我们已经使用生物工程策略来增强乳酸链球菌素针对几个引人注目的靶标的活性,包括多重耐药性临床病原体,例如耐甲氧西林的金黄色葡萄球菌,耐万古霉素的肠球菌,葡萄球菌以及与牛乳腺炎相关的链球菌。我们还确定了乳链菌肽衍生物具有增强的能力,损害生物膜的形成和降低耐甲氧西林的假丝酵母的生物膜的密度。本研究旨在评估乳链菌肽和乳链菌肽衍生物提高常规抗生素功效的潜力,并评估杀死和/或根除多种葡萄球菌靶标与生物膜相关的细胞的可能性。基于生长曲线的比较确定,与等效乳链菌肽A +抗生素组合或每种抗生素相比,乳链菌肽nisin V +青霉素或nisin I4V +氯霉素的组合分别对金黄色葡萄球菌SA113和pseudintermedius DSM21284具有增强的抑制作用。被单独管理。此外,与乳链菌肽A +抗生素组合相比,用乳链菌肽V +氯霉素和乳链菌肽I4V +氯霉素组合处理的已建立生物膜的代谢活性分别显示金黄色葡萄球菌SA113和假单胞菌DSM21284生物膜活力显着降低。快速比色XTT分析。结果表明,乳酸链球菌肽衍生物和抗生素组合的活性比野生型乳酸链球菌素和抗生素组合的活性显着提高,值得进一步研究,以将其用作抗生物膜剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号